- Home
- BIIB vs ILMN Comparison
BIIB vs ILMN Comparison
Compare BIIB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ILMN
- Stock Information
- Founded
- BIIB 1978
- ILMN 1998
- Country
- BIIB United States
- ILMN United States
- Employees
- BIIB N/A
- ILMN N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ILMN Medical Specialities
- Sector
- BIIB Health Care
- ILMN Health Care
- Exchange
- BIIB Nasdaq
- ILMN Nasdaq
- Market Cap
- BIIB 25.1B
- ILMN 23.6B
- IPO Year
- BIIB 1991
- ILMN 2000
- Fundamental
- Price
- BIIB $149.02
- ILMN $135.21
- Analyst Decision
- BIIB Buy
- ILMN Buy
- Analyst Count
- BIIB 26
- ILMN 17
- Target Price
- BIIB $248.00
- ILMN $163.12
- AVG Volume (30 Days)
- BIIB 1.6M
- ILMN 2.3M
- Earning Date
- BIIB 02-11-2025
- ILMN 02-06-2025
- Dividend Yield
- BIIB N/A
- ILMN N/A
- EPS Growth
- BIIB 10.05
- ILMN N/A
- EPS
- BIIB 11.06
- ILMN N/A
- Revenue
- BIIB $9,607,500,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- BIIB N/A
- ILMN N/A
- Revenue Next Year
- BIIB N/A
- ILMN $4.05
- P/E Ratio
- BIIB $13.47
- ILMN N/A
- Revenue Growth
- BIIB N/A
- ILMN N/A
- 52 Week Low
- BIIB $145.07
- ILMN $97.36
- 52 Week High
- BIIB $268.30
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- ILMN 40.42
- Support Level
- BIIB $145.07
- ILMN $130.31
- Resistance Level
- BIIB $149.92
- ILMN $137.69
- Average True Range (ATR)
- BIIB 3.81
- ILMN 5.31
- MACD
- BIIB 0.05
- ILMN -1.10
- Stochastic Oscillator
- BIIB 22.51
- ILMN 22.85
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.